Krystal Biotech, Inc. Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYS

Pozycja w akcjach #2121
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Cena akcji
$324.41
Kapitalizacja rynkowa
$9.60B
Zmiana (1 dzień)
1.30%
Zmiana (1 rok)
65.55%
Kraj
US
Handel Krystal Biotech, Inc. (KRYS)

Kategoria

Healthcare
Wskaźnik P/B dla Krystal Biotech, Inc. (KRYS)
Wskaźnik P/B na dzień October 2026 TTM: 7.18
Według najnowszych raportów finansowych i ceny akcji Krystal Biotech, Inc., obecny wskaźnik P/B (TTM) wynosi 7.18. Na koniec 2023 wynosił 4.33.
Historia wskaźnika P/B dla Krystal Biotech, Inc. od 2016 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
2026 (TTM) 7.18 51.90%
2024 4.73 9.40%
2023 4.33 11.88%
2022 3.87 47.83%
2021 2.62 -32.22%
2020 3.86 -11.07%
2019 4.34 111.07%
2018 2.06 80.39%
2017 1.14 -99.28%
2016 157.41 0.00%
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.251 -13.00%
US
13.2547 84.49%
US
4.208 -41.43%
AU
- -
CH
6.1824 -13.95%
NL